SCHEMBL10145490

SCHEMBL10145490

Bc1c2c(cc(OC)c1OC)C(=O)N(Cc1ccc(C(=O)OC)cc1)C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ABCC1 P33527 1/20 0.42
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
FAAH O00519 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
GAA P10253 2/20 0.39
RAB9A P51151 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL448440 0.87 MEN1 (0.44) MEN1KMT2AKDM4EMAPTHSD17B10
SCHEMBL447466 0.77 ALDH1A1 (0.41) MEN1KMT2ASMN1; SMN2ALDH1A1HDAC1
SCHEMBL437082 0.75 MEN1 (0.47) MEN1KMT2AKDM4EMAPTSMN1; SMN2
SCHEMBL451834 0.73 MEN1 (0.53) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL1418461 0.71 KMT2A (0.53) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL446536 0.71 MEN1 (0.56) MEN1KMT2AALDH1A1HDAC1LMNA
SCHEMBL1417419 0.71 KMT2A (0.53) MEN1KMT2AKDM4ESMN1; SMN2ALDH1A1
SCHEMBL449975 0.71 HDAC1 (0.61) HDAC1HDAC2TUBB4ATUBBTUBA3C
SCHEMBL3975612 0.71 MAPT (0.43) MEN1KMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3980428 0.69 GAA (0.40) MEN1KMT2ASMN1; SMN2HDAC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065396-A1 ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065396-A1 ISOINDOLINONE DERIVATIVES, PREPARATION METHOD THEREOF AND A PHARMACEUTICAL COMPOSITION COMPRISING SAME PPIP5K2, SOST, ALPL MEN1 1458/4885KMT2A 2227/4885ABCC1 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.